Patients with metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD) and insulin resistance may experience improvements in hepatic steatosis and liver enzyme elevations, though this represents an off-label use with evolving evidence
Reviewers report polarized outcomes: some patients see modest results, many see no measurable response and request a switch to injectables
The B12 addition is a bonus that Wegovy does not include
Drugs.com, 2025 To view or add a comment, sign in HbA1c Out, CGM In: The New Vocabulary of Diabetes- #CGM is no longer just a glucose monitorit has become a diagnostic and prognostic tool redefining diabetes care
This off-label promotion meant millions of otherwise healthy individuals were prescribed Ozempic for weight management without understanding they were taking a powerful medication with serious adverse effects
This was replicated for others, but not in all studies published that look at this